纽约，2026 年 1 月 7 日（全球新闻通讯社）—— Bright Minds Biosciences Inc. (CSE: DRUG) (NASDAQ: DRUG)（“ Bright Minds” 或 “ 公司”）宣布其之前公布的公开发行 1,945,000 股公司普通股（“ 普通股”）的定价，发行价格为每股 90.00 美元，预计总收益为 175,050,000 美元（“ 发行”）。与此次发行相关，公司已授予承销商 30 天的选择权，以公开发行价格购买最多 291,750 股普通股，扣除承销折扣和佣金。此次发行中出售的所有证券均由 Bright Minds 提供。
此次发行的完成预计将在 2026 年 1 月 9 日进行，前提是满足惯常的交割条件。
公司计划将此次发行的净收益用于资助未来的临床试验，包括针对缺失性癫痫、重度癫痫发作（DEE）和普拉德 - 威利综合症的药物候选者的试验，以及启动 BMB-105 的第一阶段临床药物试验，并对早期阶段项目进行额外的研究和开发工作，以及用于一般公司和营运资金目的。
Jefferies、TD Cowen、Piper Sandler  Co.和 Cantor 担任此次发行的联合账簿管理人。
公司已向美国证券交易委员会（“ SEC”）提交了 F-3 表格的货架注册声明（“ 注册声明”），该声明于 2025 年 9 月 2 日获得 SEC 的有效声明。此次发行仅通过构成注册声明一部分的招股说明书和招股说明书补充进行。与此次发行相关的初步招股说明书补充和招股说明书的副本已提交给 SEC。在您投资之前，您应阅读该注册声明中的招股说明书以及公司向 SEC 提交的其他文件，以获取有关公司和此次发行的更多信息。您可以通过访问 SEC 网站的 EDGAR 获取这些文件，网址为 www.sec.gov。此次发行的最终条款将在提交给 SEC 的最终招股说明书补充中披露。与此次发行相关的初步招股说明书补充和招股说明书，以及一旦可用的最终招股说明书补充的副本，可以从以下渠道获得：（i）Jefferies LLC，注意：股权承销招股说明书部门，520 Madison Avenue, New York, New York 10022，电话（877）821-7388 或通过电子邮件联系 Prospectus_Department@Jefferies.com，（ii）TD Securities (USA) LLC，c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717，或通过电子邮件联系 TDManualrequest@broadridge.com，（iii）Piper Sandler  Co.，注意：招股说明书部门，350 North 5th Street, Suite 1000, Minneapolis, Minnesota 55401，或电话（800）747-3924，或通过电子邮件联系 prospectus@psc.com，或（iv）Cantor Fitzgerald  Co.，注意：资本市场，110 East 59th Street, 6th Floor, New York, New York 10022，或通过电子邮件联系 prospectus@cantor.com。
终止 ATM
公司还宣布，在定价此次发行的过程中，公司已终止与 Piper Sandler  Co.和 Cantor Fitzgerald  Co.（统称为 “ 代理”）签订的 2025 年 8 月 25 日的股权分配协议（“ EDA”），该协议提供了一项市场内股权发行计划（“ ATM”），该终止自今日生效。ATM 之前允许公司通过代理发行和出售普通股，累计销售额最高可达 1 亿美元。
本新闻稿不构成出售这些证券的要约或购买这些证券的要约请求，也不应在任何州或司法管辖区内进行这些证券的出售，若在该州或司法管辖区内的证券法规定下，未进行注册或资格审查，任何要约、请求或购买要约或任何证券的销售将根据 1933 年证券法的注册要求进行。
关于 Bright Minds
Bright Minds 是一家生物技术公司，致力于为神经和精神疾病患者开发创新治疗方案。我们的产品线包括针对大脑中关键受体的新型化合物，以应对高未满足医疗需求的疾病，包括癫痫、抑郁症和其他中枢神经系统疾病。Bright Minds 专注于提供能够改变患者生活的突破性疗法。
Bright Minds 开发了一种独特的平台，具有高度选择性的血清素激动剂，表现出对不同血清素受体的选择性。这为神经学和精神病学领域提供了丰富的新化合物（NCE）项目组合。
联系信息
Alex Vasilkevich
首席运营官
Bright Minds Biosciences Inc.
电话：414-731-6422
电子邮件：alex@brightmindsbio.com
投资者关系
Lisa M. Wilson
电话：212-452-2793
电子邮件：lwilson@insitecony.com
加拿大证券交易所对本新闻稿的内容既未批准也未否决。
前瞻性信息
本文件包含基于公司截至声明日期的预期、估计和预测的 “前瞻性声明”。通常，这些前瞻性声明可以通过使用 “前景”、“预期”、“项目”、“目标”、“相信”、“估计”、“期望”、“打算”、“应该” 和类似表达来识别。本新闻稿中所作的前瞻性声明包括关于根据此次发行销售证券和公司使用发行收益的声明。
前瞻性声明受到已知和未知的风险、不确定性及其他因素的影响，这些因素可能导致公司的实际结果、活动水平、业绩或成就与这些前瞻性声明所表达或暗示的内容存在重大差异。这些因素包括但不限于：
<ul>
<li>一般经济状况、金融市场、通货膨胀和利率的变化，汇率波动，特别是与美元和加元的价值相关，以及资本和融资的持续可用性；</li>
<li>与制药公司相关的固有风险，包括潜在药物候选者测试结果的结果、遵守公司运营或可能运营的所有司法管辖区的监管要求，以及竞争；</li>
<li>保险不足或无法获得保险以覆盖运营风险的风险；</li>
<li>我们遵守我们业务所受的广泛政府监管的能力；</li>
<li>与意外的司法或监管程序相关的不确定性；</li>
<li>影响我们知识产权、临床前和临床药物试验的法律、法规和政府政策的变化及其影响；</li>
<li>诉讼风险和诉讼固有的不确定性；</li>
<li>我们对关键管理和运营人员的依赖；</li>
<li>我们所处的竞争环境；</li>
<li>我们用于报告财务状况的会计政策和方法变化的风险，包括与关键会计假设和估计相关的不确定性；</li>
<li>管理层讨论与分析（“MD&amp;A”）、季度报告和向证券监管机构提交的重大变更报告，以及在 “风险因素” 标题下讨论的那些风险；以及</li>
<li>拟议的发行是否会完成，以及与预期收益使用相关的风险和不确定性。</li>
</ul>
有关 Bright Minds 的更多信息，投资者应查看公司向美国证券交易委员会提交的年度 40-F 表格，网址为 www.sec.gov，以及在 www.sedarplus.ca 上可获得的本国管辖区文件，包括我们年度信息表中包含的 “风险因素”。
<img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZeU1qQXdOeU0zTXpVd05qY3lJekl5T1RRNE9UZz0?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZeU1qQXdOeU0zTXpVd05qY3lJekl5T1RRNE9UZz0"/>
<img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/NDUwYjdkZDgtZmViYy00OTk3LWExNjAtZDVjYTg3NGM4MmRjLTEzMDY0NDgtMjAyNi0wMS0wOC1lbg==/tiny/Bright-Minds-Biosciences.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/NDUwYjdkZDgtZmViYy00OTk3LWExNjAtZDVjYTg3NGM4MmRjLTEzMDY0NDgtMjAyNi0wMS0wOC1lbg==/tiny/Bright-Minds-Biosciences.png"/>

DRUG

Bright Minds Biosciences Inc. 宣布以每股 90.00 美元的价格公开发行 1,945,000 股普通股，目标总收益为 1.75 亿美元。此次发行包括承销商在 30 天内购买额外 291,750 股的选择权。收益将用于资助针对缺失性癫痫、发展性癫痫综合症（DEE）和普拉德 - 威利综合症等药物候选者的临床试验。此次发行预计将于 2026 年 1 月 9 日完成。该公司还终止了之前的市场发行股票计划

NEW YORK, Jan. 07, 2026 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE: DRUG) (NASDAQ: DRUG) (“ Bright Minds” or the “ Company”) announces the pricing of its previously announced public offering of 1,945,000 common shares in the capital of the Company (the “ Common Shares”) at a price of $90.00 per Common Share for anticipated gross proceeds of $175,050,000 (the “ Offering”). In connection with the Offering, the Company has granted the underwriters a 30-day option to purchase up to an additional 291,750 Common Shares at the public offering price, less underwriting discounts and commissions. All of the securities being sold in this Offering are being offered by Bright Minds.
<div class="lb-trans">纽约，2026 年 1 月 7 日（全球新闻通讯社）—— Bright Minds Biosciences Inc. (CSE: DRUG) (NASDAQ: DRUG)（“ Bright Minds” 或 “ 公司”）宣布其之前公布的公开发行 1,945,000 股公司普通股（“ 普通股”）的定价，发行价格为每股 90.00 美元，预计总收益为 175,050,000 美元（“ 发行”）。与此次发行相关，公司已授予承销商 30 天的选择权，以公开发行价格购买最多 291,750 股普通股，扣除承销折扣和佣金。此次发行中出售的所有证券均由 Bright Minds 提供。
</div>The closing of the Offering is expected to occur on January 9, 2026 subject to the satisfaction of customary closing conditions.
<div class="lb-trans">此次发行的完成预计将在 2026 年 1 月 9 日进行，前提是满足惯常的交割条件。
</div>The Company intends to use the net proceeds from the Offering to fund future clinical trials for the Company’s drug candidates, including for absence seizures, DEE, and Prader-Willi Syndrome, as well as initiation of phase 1 clinical drug trials for BMB-105, and additional research and development work on earlier phase programs, as well as for general corporate and working capital purposes.
<div class="lb-trans">公司计划将此次发行的净收益用于资助未来的临床试验，包括针对缺失性癫痫、重度癫痫发作（DEE）和普拉德 - 威利综合症的药物候选者的试验，以及启动 BMB-105 的第一阶段临床药物试验，并对早期阶段项目进行额外的研究和开发工作，以及用于一般公司和营运资金目的。
</div>Jefferies, TD Cowen, Piper Sandler &amp; Co., and Cantor are acting as joint book-running managers for the Offering.
<div class="lb-trans">Jefferies、TD Cowen、Piper Sandler  Co.和 Cantor 担任此次发行的联合账簿管理人。
</div>The Company has filed a shelf registration statement on Form F-3 (the “ Registration Statement”) with the U.S. Securities and Exchange Commission (“ SEC”) which was declared effective by the SEC on September 2, 2025. The Offering is being made solely by means of a prospectus and a prospectus supplement that form a part of the Registration Statement. A copy of the preliminary prospectus supplement and accompanying prospectus relating to this Offering has been filed with the SEC. Before you invest, you should read the prospectus in that Registration Statement and other documents the Company has filed with the SEC for more information about the Company and the Offering. You may get these documents for free by visiting EDGAR on the SEC website at www.sec.gov. The final terms of the Offering will be disclosed in a final prospectus supplement to be filed with the SEC. Copies of the preliminary prospectus supplement and accompanying prospectus, and the final prospectus supplement, once available, relating to the Offering may be obtained from (i) Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, New York, New York 10022, by telephone at (877) 821-7388 or by email at Prospectus_Department@Jefferies.com, (ii) TD Securities (USA) LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by email at TDManualrequest@broadridge.com, (iii) Piper Sandler &amp; Co., Attention: Prospectus Department, 350 North 5th Street, Suite 1000, Minneapolis, Minnesota 55401, or by telephone at (800) 747-3924, or by e-mail at prospectus@psc.com, or (iv) Cantor Fitzgerald &amp; Co., Attention: Capital Markets, 110 East 59th Street, 6th Floor, New York, New York 10022, or by email at prospectus@cantor.com.
<div class="lb-trans">公司已向美国证券交易委员会（“ SEC”）提交了 F-3 表格的货架注册声明（“ 注册声明”），该声明于 2025 年 9 月 2 日获得 SEC 的有效声明。此次发行仅通过构成注册声明一部分的招股说明书和招股说明书补充进行。与此次发行相关的初步招股说明书补充和招股说明书的副本已提交给 SEC。在您投资之前，您应阅读该注册声明中的招股说明书以及公司向 SEC 提交的其他文件，以获取有关公司和此次发行的更多信息。您可以通过访问 SEC 网站的 EDGAR 获取这些文件，网址为 www.sec.gov。此次发行的最终条款将在提交给 SEC 的最终招股说明书补充中披露。与此次发行相关的初步招股说明书补充和招股说明书，以及一旦可用的最终招股说明书补充的副本，可以从以下渠道获得：（i）Jefferies LLC，注意：股权承销招股说明书部门，520 Madison Avenue, New York, New York 10022，电话（877）821-7388 或通过电子邮件联系 Prospectus_Department@Jefferies.com，（ii）TD Securities (USA) LLC，c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717，或通过电子邮件联系 TDManualrequest@broadridge.com，（iii）Piper Sandler  Co.，注意：招股说明书部门，350 North 5th Street, Suite 1000, Minneapolis, Minnesota 55401，或电话（800）747-3924，或通过电子邮件联系 prospectus@psc.com，或（iv）Cantor Fitzgerald  Co.，注意：资本市场，110 East 59th Street, 6th Floor, New York, New York 10022，或通过电子邮件联系 prospectus@cantor.com。
</div>Termination of ATM
<div class="lb-trans">终止 ATM
</div>The Company also announces that in connection with pricing the Offering, the Company has terminated the equity distribution agreement dated August 25, 2025 (the “ EDA”) entered into among the Company, Piper Sandler &amp; Co. and Cantor Fitzgerald &amp; Co. (collectively, the “ Agents”), providing for an at-the-market equity offering program (the “ ATM”), with such termination effective today. The ATM previously allowed the Company to issue and sell Common Shares from treasury having an aggregate gross sales amount of up to USD$100 million through the Agents.
<div class="lb-trans">公司还宣布，在定价此次发行的过程中，公司已终止与 Piper Sandler  Co.和 Cantor Fitzgerald  Co.（统称为 “ 代理”）签订的 2025 年 8 月 25 日的股权分配协议（“ EDA”），该协议提供了一项市场内股权发行计划（“ ATM”），该终止自今日生效。ATM 之前允许公司通过代理发行和出售普通股，累计销售额最高可达 1 亿美元。
</div>This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. Any offers, solicitations or offers to buy, or any sales of securities will be made in accordance with the registration requirements of the Securities Act of 1933, as amended.
<div class="lb-trans">本新闻稿不构成出售这些证券的要约或购买这些证券的要约请求，也不应在任何州或司法管辖区内进行这些证券的出售，若在该州或司法管辖区内的证券法规定下，未进行注册或资格审查，任何要约、请求或购买要约或任何证券的销售将根据 1933 年证券法的注册要求进行。
</div>About Bright Minds
<div class="lb-trans">关于 Bright Minds
</div>Bright Minds is a biotechnology company developing innovative treatments for patients with neurological and psychiatric disorders. Our pipeline includes novel compounds targeting key receptors in the brain to address conditions with high unmet medical need, including epilepsy, depression, and other CNS disorders. Bright Minds is focused on delivering breakthrough therapies that can transform patients' lives.
<div class="lb-trans">Bright Minds 是一家生物技术公司，致力于为神经和精神疾病患者开发创新治疗方案。我们的产品线包括针对大脑中关键受体的新型化合物，以应对高未满足医疗需求的疾病，包括癫痫、抑郁症和其他中枢神经系统疾病。Bright Minds 专注于提供能够改变患者生活的突破性疗法。
</div>Bright Minds has developed a unique platform of highly selective serotonergic agonists exhibiting selectivity at different serotonergic receptors. This has provided a rich portfolio of NCE programs within neurology and psychiatry.
<div class="lb-trans">Bright Minds 开发了一种独特的平台，具有高度选择性的血清素激动剂，表现出对不同血清素受体的选择性。这为神经学和精神病学领域提供了丰富的新化合物（NCE）项目组合。
</div>Contact Information
<div class="lb-trans">联系信息
</div>Alex Vasilkevich
<div class="lb-trans">Alex Vasilkevich
</div>Chief Operating Officer
<div class="lb-trans">首席运营官
</div>Bright Minds Biosciences Inc.
<div class="lb-trans">Bright Minds Biosciences Inc.
</div>T: 414-731-6422
<div class="lb-trans">电话：414-731-6422
</div>E: alex@brightmindsbio.com
<div class="lb-trans">电子邮件：alex@brightmindsbio.com
</div>Investor Relations
<div class="lb-trans">投资者关系
</div>Lisa M. Wilson
<div class="lb-trans">Lisa M. Wilson
</div>T: 212-452-2793
<div class="lb-trans">电话：212-452-2793
</div>E: lwilson@insitecony.com
<div class="lb-trans">电子邮件：lwilson@insitecony.com
</div>The Canadian Securities Exchange has neither approved nor disapproved the contents of this news release.
<div class="lb-trans">加拿大证券交易所对本新闻稿的内容既未批准也未否决。
</div>Forward-Looking Information
<div class="lb-trans">前瞻性信息
</div>This document contains “forward-looking statements” that were based on the Company’s expectations, estimates and projections as of the dates those statements were made. Generally, these forward-looking statements can be identified by the use of forward-looking terminology such as “outlook”, “anticipate”, “project”, “target”, “believe”, “estimate”, “expect”, “intend”, “should” and similar expressions. Forward-looking statements made in this news release include statements regarding the sales of securities pursuant to the Offering and the Company’s use of proceeds from the Offering.
<div class="lb-trans">本文件包含基于公司截至声明日期的预期、估计和预测的 “前瞻性声明”。通常，这些前瞻性声明可以通过使用 “前景”、“预期”、“项目”、“目标”、“相信”、“估计”、“期望”、“打算”、“应该” 和类似表达来识别。本新闻稿中所作的前瞻性声明包括关于根据此次发行销售证券和公司使用发行收益的声明。
</div>Forward-looking statements are subject to known and unknown risks, uncertainties and other factors that may cause the Company’s actual results, level of activity, performance or achievements to be materially different from those expressed or implied by such forward-looking statements. These included but are not limited to:
<div class="lb-trans">前瞻性声明受到已知和未知的风险、不确定性及其他因素的影响，这些因素可能导致公司的实际结果、活动水平、业绩或成就与这些前瞻性声明所表达或暗示的内容存在重大差异。这些因素包括但不限于：
</div><ul>
<li>changes in general economic conditions, the financial markets, inflation and interest rates, fluctuations in exchange rates, particularly with respect to the value of the U.S. dollar and Canadian dollar, and the continued availability of capital and financing;</li>
<li>inherent risks associated with pharmaceutical companies, including with respect to outcomes of testing of potential drug candidates, compliance with regulatory requirements from all jurisdictions in which the Company operates or may operate, and competition;</li>
<li>the risk of inadequate insurance or inability to obtain insurance to cover operational risks;</li>
<li>our ability to comply with the extensive governmental regulation to which our business is subject;</li>
<li>uncertainties related to unexpected judicial or regulatory proceedings;</li>
<li>changes in, and the effects of, the laws, regulations and government policies affecting our intellectual property, pre-clinical and clinical drug trials;</li>
<li>litigation risks and the inherent uncertainty of litigation;</li>
<li>our reliance upon key management and operating personnel;</li>
<li>the competitive environment in which we operate;</li>
<li>the risk of changes in accounting policies and methods we use to report our financial condition, including uncertainties associated with critical accounting assumptions and estimates;</li>
<li>Management Discussion and Analysis (“MD&amp;A”), quarterly reports and material change reports filed with and furnished to securities regulators, and those risks which are discussed under the heading “Risk Factors”; and</li>
<li>whether or not the proposed Offering will be completed, and the risks and uncertainties related to the expected use of proceeds.</li>
</ul>
<div class="lb-trans"><ul>
<li>一般经济状况、金融市场、通货膨胀和利率的变化，汇率波动，特别是与美元和加元的价值相关，以及资本和融资的持续可用性；</li>
<li>与制药公司相关的固有风险，包括潜在药物候选者测试结果的结果、遵守公司运营或可能运营的所有司法管辖区的监管要求，以及竞争；</li>
<li>保险不足或无法获得保险以覆盖运营风险的风险；</li>
<li>我们遵守我们业务所受的广泛政府监管的能力；</li>
<li>与意外的司法或监管程序相关的不确定性；</li>
<li>影响我们知识产权、临床前和临床药物试验的法律、法规和政府政策的变化及其影响；</li>
<li>诉讼风险和诉讼固有的不确定性；</li>
<li>我们对关键管理和运营人员的依赖；</li>
<li>我们所处的竞争环境；</li>
<li>我们用于报告财务状况的会计政策和方法变化的风险，包括与关键会计假设和估计相关的不确定性；</li>
<li>管理层讨论与分析（“MD&amp;A”）、季度报告和向证券监管机构提交的重大变更报告，以及在 “风险因素” 标题下讨论的那些风险；以及</li>
<li>拟议的发行是否会完成，以及与预期收益使用相关的风险和不确定性。</li>
</ul>
</div>For further information on Bright Minds, investors should review the Company’s annual Form 40-F filing with the United States Securities and Exchange Commission available at www.sec.gov and home jurisdiction filings that are available at www.sedarplus.ca, including the “Risk Factors” included in our Annual Information Form.
<div class="lb-trans">有关 Bright Minds 的更多信息，投资者应查看公司向美国证券交易委员会提交的年度 40-F 表格，网址为 www.sec.gov，以及在 www.sedarplus.ca 上可获得的本国管辖区文件，包括我们年度信息表中包含的 “风险因素”。
</div><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZeU1qQXdOeU0zTXpVd05qY3lJekl5T1RRNE9UZz0" alt="" original-src="https://www.globenewswire.com/newsroom/ti?nf=OTYyMjAwNyM3MzUwNjcyIzIyOTQ4OTg="/>
<img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/NDUwYjdkZDgtZmViYy00OTk3LWExNjAtZDVjYTg3NGM4MmRjLTEzMDY0NDgtMjAyNi0wMS0wOC1lbg==/tiny/Bright-Minds-Biosciences.png" alt="" original-src="https://ml.globenewswire.com/media/NDUwYjdkZDgtZmViYy00OTk3LWExNjAtZDVjYTg3NGM4MmRjLTEzMDY0NDgtMjAyNi0wMS0wOC1lbg==/tiny/Bright-Minds-Biosciences.png"/>

Bright Minds Biosciences 宣布扩大至 1.75 亿美元的普通股公开发行定价 | DRUG 股票新闻